

Giovanni Caocci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5547112/publications.pdf>

Version: 2024-02-01

201
papers

3,700
citations

136950

32
h-index

168389

53
g-index

202
all docs

202
docs citations

202
times ranked

4714
citing authors

#	ARTICLE	IF	CITATIONS
1	Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 291-300.	3.3	3
2	Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. <i>Annals of Hematology</i> , 2022, 101, 929-931.	1.8	19
3	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	2.5	20
4	Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy. <i>Annals of Hematology</i> , 2022, 101, 749-754.	1.8	3
5	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 442-459.	0.4	7
6	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IFOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	2.5	7
7	Conditioning Regimens in Patients with β^2 -Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 907.	2.4	9
8	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	2.8	5
9	International validation of the EORTC QLQ-C15-PAL questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 431-441.	2.5	6
10	Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination. <i>Haematologica</i> , 2022, 107, 1222-1225.	3.5	19
11	Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications. <i>Leukemia Research</i> , 2022, 117, 106856.	0.8	5
12	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	1.3	10
13	Perls Stain Grade in Bone Marrow Aspirate Correlates with Overall Survival in Low-Risk Myelodysplastic Patients. <i>Acta Haematologica</i> , 2021, 144, 332-336.	1.4	1
14	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	2.5	19
15	Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. <i>Acta Haematologica</i> , 2021, 144, 322-326.	1.4	0
16	Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment. <i>Journal of Palliative Medicine</i> , 2021, 24, 397-404.	1.1	9
17	Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia. <i>Annals of Hematology</i> , 2021, , 1.	1.8	1
18	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	6.2	41

#	ARTICLE	IF	CITATIONS
19	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	1.7	9
20	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	1.7	8
21	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219.	1.8	4
22	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	4.1	14
23	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021, 138, 571-583.	1.4	26
24	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816.	7.2	3
25	The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. <i>Journal of Public Health Research</i> , 2021, 10, .	1.2	2
26	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	2.8	6
27	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	5.0	11
28	Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 674748.	3.5	7
29	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	1.8	14
30	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	1.4	1
31	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581.	1.4	1
32	Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 307-314.	1.2	4
33	Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 264-270.	1.2	4
34	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	1.7	21
35	Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core™ an adaptive measure of core quality of life domains in oncology clinical practice and research. <i>Journal of Clinical Epidemiology</i> , 2020, 117, 117-125.	5.0	12
36	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	7.2	35

#	ARTICLE	IF	CITATIONS
37	Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. <i>Journal of Clinical Epidemiology</i> , 2020, 118, 1-8.	5.0	184
38	Systemic Mastocytosis with Associated Primary Myelofibrosis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 442-443.	0.6	2
39	Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 363-365.	1.8	3
40	White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. <i>Chemotherapy</i> , 2020, 65, 110-114.	1.6	4
41	Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3106-3108.	3.8	12
42	Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020066.	1.3	7
43	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	2.7	14
44	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	2.4	2
45	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	1.7	1
46	Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH. <i>Blood</i> , 2020, 136, 3082-3085.	1.4	0
47	Defibrotide in the COVID-19 coagulopathy: What is the timing?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3116-3118.	3.8	4
48	Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2132-2134.	0.5	2
49	Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?. <i>Annals of Hematology</i> , 2020, 99, 1675-1676.	1.8	14
50	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	1.8	9
51	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	6.2	6
52	Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. <i>American Journal of Hematology</i> , 2020, 95, E260-E263.	4.1	15
53	Rectal involvement in pre-early T acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2020, 99, 1151-1152.	1.8	0
54	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	1.6	2

#	ARTICLE	IF	CITATIONS
55	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	7.2	14
56	Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting. <i>International Journal of Hematology</i> , 2020, 111, 614-618.	1.6	6
57	Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1180.	2.4	9
58	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020, 136, 35-36.	1.4	1
59	Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) Tj ETQq1 1 0.78434 4 rgBT4Overload	1.4	4
60	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44.	1.4	2
61	Health Related Quality of Life in Patients with Onco-hematological Diseases. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2020, 16, 174-179.	1.2	15
62	Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 12609-12622.	0.7	31
63	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
64	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020, 136, 17-18.	1.4	1
65	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
66	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	1.4	0
67	Identification of a Predictive Pre-Chemotherapy Score for Febrile Neutropenia - the Fnipi INDEX. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
68	First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
69	The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 51-57.	4.4	7
70	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019, 22, 1303-1310.	0.3	18
71	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	1.8	5
72	A real-world study on Clofarabine and Cytarabine combination in patients with relapsed/refractory acute myeloid leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019032.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	1.8	10
74	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	1.7	19
75	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	1.7	53
76	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	3.5	58
77	Acute basophilic leukemia with U2AF1 mutation. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 76, 63-65.	1.4	3
78	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	1.5	28
79	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	5.2	66
80	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019, 134, 4145-4145.	1.4	3
81	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649.	1.4	7
82	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	1.4	2
83	Validation of the EORTC QLQ-C30 Summary Score in patients with hematological malignancies. <i>Journal of Clinical Oncology</i> , 2019, 37, e18551-e18551.	1.6	4
84	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients. <i>Journal of Clinical Oncology</i> , 2019, 37, e18220-e18220.	1.6	0
85	Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4160-4160.	1.4	0
86	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4188-4188.	1.4	0
87	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019, 134, 4153-4153.	1.4	0
88	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	1.4	1
89	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174.	1.4	2
90	Increased Incidence of Infection in Patients with Myelofibrosis and Transfusion-Associated Iron Overload: A Monocentric Experience. <i>Blood</i> , 2019, 134, 4186-4186.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients. <i>Blood</i> , 2019, 134, 1714-1714.	1.4	0
92	Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 4144-4144.	1.4	2
93	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018, 97, 745-754.	1.8	11
94	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	4.1	26
95	Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation. <i>Leukemia Research Reports</i> , 2018, 9, 14-15.	0.4	6
96	Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis. <i>Acta Haematologica</i> , 2018, 139, 164-165.	1.4	4
97	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	4.1	31
98	International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. <i>Quality of Life Research</i> , 2018, 27, 333-345.	3.1	33
99	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	2.8	84
100	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	1.4	1
101	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006.	1.4	1
102	Perl's Stain Grade in the Bone Marrow Aspirate Correlates with Overall Survival in Low Risk Myelodysplastic Patients. <i>Blood</i> , 2018, 132, 5517-5517.	1.4	2
103	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018, 132, 45-45.	1.4	4
104	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	1.4	3
105	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	1.4	8
106	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	1.4	3
107	PICC Insertion and Management in Hodgkin Lymphoma Patients: A 10-YEARS Monocentric Prospective Study. <i>Blood</i> , 2018, 132, 5844-5844.	1.4	0
108	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2558-2564.	1.3	8
110	Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 733-737.	1.5	0
111	HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. <i>Leukemia Research</i> , 2017, 61, 1-5.	0.8	12
112	Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. <i>American Journal of Hematology</i> , 2017, 92, 1303-1310.	4.1	52
113	Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib. <i>Experimental Hematology</i> , 2017, 55, 71-75.	0.4	2
114	KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation. <i>PLoS ONE</i> , 2017, 12, e0180831.	2.5	57
115	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	1.8	14
116	Low Impact of Genetic Modifiers on the Phenotype of Homozygous Beta Thalassemia in the Last Decennial Cohort of Thalassemia Newborns in Sardinia. <i>Blood</i> , 2017, 130, 951-951.	1.4	0
117	What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016048.	1.3	10
118	BONE MARROW HOMING AND ENGRAFTMENT DEFECTS OF HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017032.	1.3	26
119	HLA-G expression and role in advanced-stage classical Hodgkin lymphoma. <i>European Journal of Histochemistry</i> , 2016, 60, 2606.	1.5	22
120	Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis. <i>PLoS ONE</i> , 2016, 11, e0146086.	2.5	26
121	Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2016, 91, 1056-1056.	4.1	0
122	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 63.	17.0	18
123	Ruxolitinib therapy and telomere length in myelofibrosis. <i>Blood Cancer Journal</i> , 2016, 6, e479-e479.	6.2	3
124	A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 1034-1038.	0.4	4
125	Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors. <i>Bone Marrow Transplantation</i> , 2016, 51, 1640-1641.	2.4	9
126	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , 2016, 91, 995-1001.	4.1	53

#	ARTICLE	IF	CITATIONS
127	The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 26.	17.0	9
128	Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 1215-1218.	1.3	5
129	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016, 128, 942-942.	1.4	2
130	How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocytopenic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2016, 128, 5472-5472.	1.4	0
131	Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 1242-1242.	1.4	0
132	Ruxolitinib Restores Normal Telomere Length in Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 3116-3116.	1.4	1
133	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. <i>Blood</i> , 2016, 128, 3951-3951.	1.4	0
134	T cell tyrosine phosphorylation response to transient redox stress. <i>Cellular Signalling</i> , 2015, 27, 777-788.	3.6	9
135	Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 542-554.	4.4	35
136	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	10.7	76
137	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2015, 43, 1015-1018.e1.	0.4	51
138	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865.	0.8	17
139	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	2.5	59
140	Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study. <i>Blood</i> , 2015, 126, 1693-1693.	1.4	1
141	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , 2015, 126, 2099-2099.	1.4	0
142	Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. <i>Blood</i> , 2015, 126, 1570-1570.	1.4	0
143	IMMUNOLOGICAL DEREGLATION IN HODGKIN'S DISEASE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014039.	1.3	17
144	Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. <i>Leukemia</i> , 2014, 28, 225-227.	7.2	111

#	ARTICLE	IF	CITATIONS
145	Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 462-463.	1.3	1
146	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). <i>European Journal of Haematology</i> , 2014, 92, 527-536.	2.2	90
147	Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 295.	0.8	2
148	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454.	1.2	38
149	Reassessing the approach to informed consent: the case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients. <i>Philosophy, Ethics, and Humanities in Medicine</i> , 2014, 9, 13.	1.5	4
150	International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. <i>Quality of Life Research</i> , 2014, 23, 825-836.	3.1	67
151	Leucocyte classification for leukaemia detection using image processing techniques. <i>Artificial Intelligence in Medicine</i> , 2014, 62, 179-191.	6.5	214
152	Homozygosity for Killer Immunoglobulin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 133-133.	1.4	1
153	Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab. <i>Blood</i> , 2014, 124, 4397-4397.	1.4	1
154	Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma. <i>Human Immunology</i> , 2013, 74, 1288-1294.	2.4	9
155	Guillain-Barré syndrome after human herpesvirus-6 reactivation in unrelated hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2013, 54, 1332-1333.	1.3	7
156	Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2013, 41, 424-431.	0.4	32
157	Early Death in Two Patients with Acute Promyelocytic Leukemia Presenting the bcr3 Isoform, FLT3-ITD Mutation, and Elevated WT1 Level. <i>Case Reports in Hematology</i> , 2013, 2013, 1-3.	0.4	2
158	Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript. <i>Case Reports in Hematology</i> , 2013, 2013, 1-2.	0.4	4
159	Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation. <i>Case Reports in Hematology</i> , 2013, 2013, 1-2.	0.4	3
160	Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. <i>Blood</i> , 2013, 122, 2262-2270.	1.4	91
161	Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes. <i>Journal of Nephrology</i> , 2013, 26, 1170-1178.	2.0	13
162	Ethical concerns surrounding the conception of an HLA compatible child for medical purposes. <i>Haematologica</i> , 2012, 97, e33-e33.	3.5	2

#	ARTICLE	IF	CITATIONS
163	Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. <i>Blood</i> , 2012, 120, 473-476.	1.4	170
164	Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?. <i>Annals of Hematology</i> , 2012, 91, 1371-1381.	1.8	51
165	Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia. <i>Human Immunology</i> , 2012, 73, 282-286.	2.4	18
166	Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 652-654.	2.0	54
167	Health related quality of life in Middle Eastern children with beta-thalassemia. <i>BMC Blood Disorders</i> , 2012, 12, 6.	0.9	61
168	Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib. <i>Leukemia Research</i> , 2012, 36, e206-e208.	0.8	9
169	Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm. <i>British Journal of Haematology</i> , 2012, 156, 118-128.	2.5	13
170	Deferasirox Chelation Therapy in Transfusion Dependent MDS Patients. Final Report From the Gimema MDS0306 Prospective Trial. <i>Blood</i> , 2012, 120, 425-425.	1.4	5
171	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population. <i>Blood</i> , 2012, 120, 2056-2056.	1.4	0
172	Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry. <i>Blood</i> , 2012, 120, 3850-3850.	1.4	0
173	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. <i>Blood</i> , 2012, 120, 3163-3163.	1.4	0
174	Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML. <i>Clinical Management Issues</i> , 2012, 6, 15-18.	0.3	0
175	Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 861-866.	2.0	52
176	The Usefulness of Artificial Neural Networks in Predicting the Outcome of Hematopoietic Stem Cell Transplantation. , 2011, , .		0
177	Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients. <i>BMC Medical Ethics</i> , 2011, 12, 4.	2.4	13
178	International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2011, 118, 3132-3132.	1.4	4
179	Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 2078-2078.	1.4	0
180	Comparison between an artificial neural network and logistic regression in predicting acute graft-vs-host disease after unrelated donor hematopoietic stem cell transplantation in thalassemia patients. <i>Experimental Hematology</i> , 2010, 38, 426-433.	0.4	32

#	ARTICLE	IF	CITATIONS
181	Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR-ABL oncoprotein and JAK2V617F mutation. <i>Leukemia Research</i> , 2010, 34, e27-e29.	0.8	11
182	The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia. <i>Bone Marrow Transplantation</i> , 2010, 45, 1618-1624.	2.4	21
183	Hemoglobin Fluctuations and Correlation with Quality of Life and Fatigue. , 2010, , 1867-1879.		0
184	Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial. <i>Blood</i> , 2010, 116, 2928-2928.	1.4	0
185	Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2009, 2, 69-80.	2.2	40
186	Familial occurrence of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 854-856.	1.3	3
187	Different Perception of Surgical Risks Between Physicians and Patients Undergoing Laparoscopic Cholecystectomy. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2009, 19, 305-311.	0.8	14
188	Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. <i>Leukemia</i> , 2008, 22, 2127-2128.	7.2	32
189	Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. <i>British Journal of Haematology</i> , 2008, 143, 548-551.	2.5	60
190	Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. <i>Haematologica</i> , 2008, 93, 1385-1388.	3.5	122
191	A simulated case of chronic myeloid leukemia: The growing risk of Munchausen's syndrome by internet. <i>Leukemia and Lymphoma</i> , 2008, 49, 1826-1828.	1.3	10
192	Status of Donor-Recipient HLA Class I Ligands and Not the KIR Genotype Is Predictive for the Outcome of Unrelated Hematopoietic Stem Cell Transplantation in Beta-Thalassemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1358-1368.	2.0	28
193	A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue. <i>Leukemia Research</i> , 2007, 31, 249-252.	0.8	32
194	The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. <i>British Journal of Haematology</i> , 2007, 139, 284-288.	2.5	52
195	Long-term efficacy and tolerance of rituximab for post-transfusional alloimmune haemolytic anaemia in a thalassaemia patient. <i>British Journal of Haematology</i> , 2007, 140, 071003043930001-???	2.5	2
196	Decision-making in adult thalassemia patients undergoing unrelated bone marrow transplantation: quality of life, communication and ethical issues. <i>Bone Marrow Transplantation</i> , 2006, 37, 165-169.	2.4	30
197	Overcoming scientific barriers and human prudence. <i>Bone Marrow Transplantation</i> , 2006, 38, 829-830.	2.4	0
198	Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. <i>Leukemia</i> , 2006, 20, 2217-2218.	7.2	31

#	ARTICLE	IF	CITATIONS
199	Unrelated Bone Marrow Transplantation for β^2 -Thalassemia Patients: The Experience of the Italian Bone Marrow Transplant Group. <i>Annals of the New York Academy of Sciences</i> , 2005, 1054, 186-195.	3.8	135
200	Unrelated donor stem cell transplantation in adult patients with thalassemia. <i>Bone Marrow Transplantation</i> , 2005, 36, 971-975.	2.4	65
201	Unrelated bone marrow transplantation in thalassemia. The experience of the Italian Bone Marrow Transplant Group (GITMO). <i>Haematologica</i> , 2002, 87, 58-61.	3.5	3